AIDS CLINICAL TRIALS GROUP - ACTU

描述（改编自申请摘要）：自成立以来 1987年，辛辛那提大学（UC）ACTU为 ACTG在一些关键领域的总体使命。 UC ACTU已经 提供了科学和行政领导，特别是在 机会性感染，最近，在抗逆转录病毒研究中， 相关神经系统疾病、研究护理和研究设计。 在 在当前周期中，UC ACTU提议继续进行广泛的 临床试验和子研究，以确保UC ACTU对 ACTG研究议程的目标。 其中包括翻译 在UC进行的关于免疫发病机制的基础研究结果 卡氏肺孢子虫和其他可能有助于确定 在抗逆转录病毒治疗中，何时以及是否可以安全地停止预防 响应者。 此外，探索微生物和免疫措施， 预防肺孢子虫病的风险作为预防性免疫的基础- 基础治疗和预防。 除了研究发病机制和 在HARRT时代丙型肝炎/HIV合并感染的临床意义，以及 利用这些知识来改进治疗方法。 另一个目标是继续 阐明HIV神经发病机制的潜在机制 感染，并利用这些机制开发新的治疗方法， 中枢神经系统HIV感染的方式，包括HIV痴呆 和多灶性白质脑病 UC ACTU还将致力于开发 治疗反应不一致患者的治疗策略 目前的抗逆转录病毒疗法，并开发简化，有效的治疗方法， 加强抗逆转录病毒治疗的战略，包括使用新药剂 从而改善临床结果。 短期和长期 与各种疾病相关的质量调整预期寿命增量成本 并会研究使用效用评估的治疗策略。 最后， 加州大学ACTU建议评估强化教育干预是否 由患者控制的起搏产生改善的短期和长期病毒学 在初治患者中抑制。

DESCRIPTION (adapted from the applicantion's abstract): Since its inception in 1987, the University of Cincinnati (UC) ACTU has made contributions to the overall mission of the ACTG in a number of key areas. The UC ACTU has provided both scientific and administrative leadership especially in opportunistic infections, and more recently, in antiretroviral studies, HIV- associated neurologic diseases, research nursing, and study design. In the current cycle, the UC ACTU proposes to continue to perform a broad range of clinical trials and substudies to assure maximum UC ACTU contribution to the objectives of the ACTG research agenda. These include to translate the findings of basic research conducted at UC on immunopathogenesis of Pneumocystis carinii and other opportunistic pathogens that may help determine when and if prophylaxis can be discontinued safely in antiretroviral therapy responders. Also, to explore microbial and immunologic measures which define risk for the protection against Pneumocystis as a basis for adjunctive immune- based therapy and prophylaxis. In addition to study the pathogenesis and clinical significance of hepatitis C/HIV co-infection in the HARRT era, and use this knowledge to develop improved treatments. Another Aim is to continue to elucidate the underlying mechanisms in the neuropathogenesis of HIV infection, and exploit these mechanisms in the development of new therapeutic modalities for central nervous system HIV infection, including HIV dementia and multifocal leukoencephalopathy. The UC ACTU will also work to develop treatment strategies for the management of patients with discordant responses to current antiretroviral therapy and to develop simplified, potent treatment strategies, including the use of novel agents, to enhance antiretroviral adherence and therefore improve clinical outcome. The short and longer-term incremental cost of quality-adjusted life expectancy associated with various treatment strategies using utility assessment will also be studied. Finally, the UC ACTU proposes to evaluate whether an intensive educational intervention that is paced by the patient yields improved short and long-term virologic suppression in naive patients.